Anika Therapeutics (ANIK) Operating Leases: 2019-2025
Historic Operating Leases for Anika Therapeutics (ANIK) over the last 7 years, with Sep 2025 value amounting to $22.8 million.
- Anika Therapeutics' Operating Leases fell 9.75% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year decrease of 9.75%. This contributed to the annual value of $24.0 million for FY2024, which is 7.34% down from last year.
- Anika Therapeutics' Operating Leases amounted to $22.8 million in Q3 2025, which was down 1.69% from $23.2 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Operating Leases registered a high of $29.7 million during Q2 2022, and its lowest value of $18.8 million during Q1 2022.
- Moreover, its 3-year median value for Operating Leases was $25.8 million (2024), whereas its average is $25.5 million.
- Per our database at Business Quant, Anika Therapeutics' Operating Leases surged by 50.27% in 2023 and then dropped by 10.56% in 2025.
- Anika Therapeutics' Operating Leases (Quarterly) stood at $19.2 million in 2021, then soared by 49.78% to $28.8 million in 2022, then declined by 10.07% to $25.9 million in 2023, then decreased by 7.34% to $24.0 million in 2024, then declined by 9.75% to $22.8 million in 2025.
- Its Operating Leases was $22.8 million in Q3 2025, compared to $23.2 million in Q2 2025 and $23.6 million in Q1 2025.